Justine Paris, a metastatic disease researcher from Université Paris Cité, and Guilhem Bousquet, a medical oncologist at Université Sorbonne Paris Nord, dive into groundbreaking findings in cancer research. They discuss PROM2 as a vital predictive biomarker for stage III melanoma, revealing its link to distant metastases and survival outcomes. Their innovative in vivo model mimics the runaway metastatic process, shedding light on mechanisms like epithelial-to-mesenchymal transition and ferroptosis resistance, with implications for renal and breast cancers as well.